




Biomarker technologies for cardiovascular health

Corporate Update Webinar
6 Aug 2024



Cardiex Webinar Participants




Craig R. Cooper
CEO



Niall Cairns
Executive Chairman



Catherine Liao
Chief Strategy Officer




Dr. Mark Gorelick
Chief Product Officer



Brian Schaechter
Senior Director of Sales –
Pharmaceutical



Rosemarie Diehl
Senior Director, Demand
Generation



Rod Hinchcliffe
Media & Capital Partners

June 2024 Quarterly Highlights



Record annual company revenues – \$12.4m.

- **Initial Pulse units arrived** in USA & Australia.
- Marketing and demand generation campaigns driving awareness and demand.
- New partnerships and pilot programs.
- **Initial Pulse production run increased to 8,000** (previously 3,000).
- **Pre-submission phase for OTC FDA-clearance for the Pulse.**
- **New patent awarded** by USPTO for wearable PPG sensor technology.
- Nearing completion of our wearable sensor validation study.
- FDA submission for wearable technology anticipated Q1 25.

Financial Overview (Q4 ending 30 June 2024)




- Revenue and other income for **FY24 of \$12.4m** (FY23 - \$6.0m)
- Q4 operating cash outflows of \$2.8m, being a significant reduction to the Q3 normalized operating outflows of \$3.4m, due to:
 - Higher cash receipts of \$0.9m in Q4 vs \$0.7m in Q3, and
 - FY23 R&D tax incentive of \$0.7m.
- **Cash resources and reserves ~ \$6.5m**, comprising:
 - \$0.5m cash; and
 - \$6.0m being funded under the Funding Commitment Agreement with C2 Ventures.
- Cash resources are believed to be sufficient to fund the Company's growth initiatives, its operations, and to meet its business objectives.


Financial Overview



Revenue



Revenue & Other Income







Product Development

CONNEQT Digital Product Suite



World-first Vascular Biometrics Monitor

CONNEQT PULSE



FDA CLEARED

April/2023



World-first Dual-Sensor Wearable Technology

Anticipated FDA clearance Q4 CY24

CONNEQT Pulse Arrival



April/2023



“It is a game-changer to be able to get regular measurements of key arterial health biomarkers in their home and work environments. I recommend that all my patients get a Pulse device even if they don’t have high blood pressure.”

Dr. Joe Raffaele





2024



**JULY
2024**

**130 Trial
Production Units
Landed in US.**
Ready for internal
testing.

**AUG
2024**

**Sign off for Mass
Production**
following
successful system
and user end-to-
end testing.

**App Store
Submission**

**SEP
2024**

**Start of Mass
Production
Phase**

**OCT
2024**

**8k Mass
Production
Units Landed
in USA**

**Mobile App &
HCP Launch**

Pulse QA & User Testing



- The Quality Assurance Team is conducting thorough system-level testing to assess the data flow from the Pulse device to both the mobile app and CONNEQT Cloud.
- The team is also evaluating the educational resources available in the CONNEQT app for their clarity and effectiveness.
- The goal is to ensure a seamless experience for the end users of the Pulse.
- The objective is to enhance user satisfaction and performance in real-world usage of the Pulse.



2024



MAR
2024

Completion of HEARTsense Wearable Study validating SphygmoCor® biomarker technology in wearables.

JUL
2024

Official publication of key wearable patent by the United States Patent and Trademark Office (USPTO) (Patent #US12,029,5380).

AUG
2024

Publication of HEARTsense Wearable Study Results in leading industry journal.

SEPT
2024

Commencement of FDA submission.



Sales & Marketing

Partner Programs



PHYSIOAGE®



Heartbeat

CONNEQT **PULSE**

Vitality starts with active monitoring of your vitals.

Track what matters® with CONNEQT Pulse.

[Join Waitlist](#)**FDA** CLEAREDPowered By
SphygmoCor®

A revolution in health management.

With CONNEQT Pulse, you can finally **access advanced arterial health screening in the comfort of your home**. Track the vascular biomarkers utilized by all the USA News & World Reports "Top US Hospitals" and receive personal support from our network of cardiologists to monitor your vascular age & arterial health.

[Join Waitlist](#)

Email Nurture



CONNEQT.
Health



Understanding Arterial Stiffness

Hi Catherine,

Thanks again for joining our waitlist for the world's most advanced home arterial health monitor.

Arterial stiffness is a critical indicator of cardiovascular health that often goes unnoticed. As we age, our arteries can lose their elasticity, becoming stiffer and less able to accommodate blood flow. This condition can lead to increased blood pressure and a higher risk of heart disease and stroke, as well as many other health disorders.

"Man is only as old as his arteries."

Thomas Sydenham (1624–1689), English Hippocrates

By regularly monitoring arterial stiffness, you can gain critical insights into your cardiovascular health, empowering you to make informed decisions and take proactive steps to maintain a healthy heart. The CONNEQT Pulse makes this

CONNEQT.
Health



Assessing Arterial Stiffness at Home


Hi Catherine,

Continuing from our last newsletter on understanding arterial stiffness, we're thrilled to introduce [CONNEQT Pulse](#), a personal arterial health monitoring system developed by Cardiex, the company behind the pioneering [SphygmoCor® technology](#). Our technology is trusted by thousands of hospitals, clinicians, and researchers worldwide, setting the gold standard for assessing arterial health.

CONNEQT Pulse uses the same clinically validated SphygmoCor® technology to provide comprehensive insights into your arterial health that standard cuff blood pressure monitors cannot. This includes key health indicators such as arterial stiffness and [central blood pressure](#), all accessible from the comfort of your home.

"New methods that assess arterial pressure and flow dynamics, beyond focus on conventional upper-arm blood pressure, are needed."

CONNEQT.
Health



Discover the Personal Health Benefits of the CONNEQT Pulse

Hi Catherine,


Imagine if you could gain deeper insights into your health and identify early signs of health concerns. [Early vascular aging](#) is one such insight, as it can affect the health of your heart, brain, kidneys, as well as your sexual health.

Deeper health insights also allow for more timely interventions that can prevent more severe health problems. We designed the [CONNEQT Pulse](#) to help you achieve this level of understanding and control over your health.

The CONNEQT Pulse is **the world's most advanced personal arterial health monitor** providing detailed information about the functionality of your arteries and the effort your heart exerts to deliver oxygenated blood to all major organs. By assessing your arterial health, the CONNEQT Pulse enables you to take proactive steps in improving overall well-being and maximizing health span.

"The future of medicine lies in empowering

CONNEQT.
Health



Hi Catherine,


Advanced arterial health management offers enlightening insights into your well-being, helping you identify early signs of potential health concerns. These insights can significantly impact the health of your heart, brain, kidneys, and more, enabling timely interventions to prevent more severe issues.

Take me, for instance. I'm an energetic 58-year-old with a family history of heart disease and was diagnosed with hypertension at age 25. For the past 33 years, I've made lifestyle changes and complemented them with blood pressure-lowering medication to keep my heart health in check. Being able to track my arterial health has been a game-changer for me.

Measurements provided by traditional cuffs - blood pressure at the arm and one's heart rate.





Pulse Waitlist Demand




Digital Presence Amplification

1. Relaunch of Cardiex.com:
 - **67%** increase in user traffic
 - **184%** increase in page views
2. Increase in online ads, programmatic advertising, and search engine marketing
3. Sponsorship of leading industry websites (JAMA, JACC, Hypertension)
4. Conclusion of our inaugural Cardiex Arterial Research Initiative, which attracted research submissions from around the globe, and garnered over 20,000 votes worldwide in the final winner selection process.



Industry Engagements and Activations



Successful webinar collaboration with American Heart Association (AHA) on "Vascular Aging", moderated by our Chief Strategy Officer, Catherine Liao



Participated in three industry events where we offered complimentary arterial assessments:

- American College of Sports Medicine (ACSM)
- North American Artery (NAA)
- Drug Information Association (DIA)

Our Focus on Pharma and Service Providers


contacts in our network



Brian Schaechter

Senior Director of Sales –
Pharmaceutical

Current Clinical Trial Opportunities Across Disease States



Devices for all Types and Phases of Clinical Trials



Phase of Clinical Trials

- Phase I
- Phase IIA (Pilot studies designed to address optimal dosing and safety)
- Phase IIB (Provides data on efficacy)
- Phase III
- Phase IV

\$5M
Current Pipeline

Types of Clinical Trials

- Site-based
- Decentralized
- Hybrid



Looking Ahead



Successful commercial launch of the Pulse

- **Multiple** new product launch, distribution and sales partnerships.
- **Continuing** brand, education, and demand generation campaigns.
- **2 additional FDA clearances.**
 - Pulse OTC ("over the counter"); and
 - CONNEQT Band
- **Strong revenue growth** from our Clinical Trial Solutions group.
- **Accelerating revenue contributions** from new product releases (SaaS, subscription, lease revenues, product sales).
- **Consistent cadence of news and investor updates** (webinars, ASX, newswires, industry journals, conferences, seminars).

Thank You

